Evidence map›Paper›PMID 38967490›Full record

ArticleMicrobiology resource announcements2024

Human gut microbiota analysis of cystic fibrosis infants using metaproteomics.

C García-Durán, C Saralegui, E Romeu, M L Hernáez, A Maruri, N Bastón-Paz, A Lamas, S Vicente, E Perez-Ruiz, I Delgado and 6 more

Abstract read
In one paragraph

Article in Microbiology resource announcements, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

C García-DuránDpto. de Microbiología y Parasitología, Universidad Complutense de Madrid and IRYCIS , Madrid, Spain.ORCID 0000-0002-0668-0903
C SaraleguiServicio de Microbiología, Hospital Universitario Ramón y Cajal and IRYCIS , Madrid, Spain.
E RomeuUnidad de Proteómica, Universidad Complutense de Madrid , Madrid, Spain.
M L HernáezUnidad de Proteómica, Universidad Complutense de Madrid , Madrid, Spain.
A MaruriServicio de Microbiología, Hospital Universitario Ramón y Cajal and IRYCIS , Madrid, Spain.
N Bastón-PazServicio de Microbiología, Hospital Universitario Ramón y Cajal and IRYCIS , Madrid, Spain.
A LamasUnidad de Fibrosis Quística, Hospital Universitario Ramón y Cajal , Madrid, Spain.
S VicenteUnidad de Fibrosis Quística, Hospital Universitario Ramón y Cajal , Madrid, Spain.
E Perez-RuizUnidad de Fibrosis Quística, Hospital Regional Universitario de Málaga , Málaga, Spain.
I DelgadoUnidad de Fibrosis Quística, Hospital Virgen del Rocío , Seville, Spain.
C Luna-ParedesSección de Neumología y Alergia Infantil, Unidad Multidisciplinar Fibrosis Quística, Hospital Doce de Octubre , Madrid, Spain.
J D CaballeroServicio de Microbiología, Hospital Universitario Ramón y Cajal and IRYCIS , Madrid, Spain.
J ZamoraUnidad de Bioestadística, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria and Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP) , Madrid, Spain.
L MonteolivaDpto. de Microbiología y Parasitología, Universidad Complutense de Madrid and IRYCIS , Madrid, Spain.ORCID 0000-0003-4949-0664
R Del CampoServicio de Microbiología, Hospital Universitario Ramón y Cajal and IRYCIS , Madrid, Spain.ORCID 0000-0003-1147-7923
C GilDpto. de Microbiología y Parasitología, Universidad Complutense de Madrid and IRYCIS , Madrid, Spain.ORCID 0000-0003-3137-2600

Funding

Comunidad de Madrid (Community of Madrid) B2017/BMD3691Fundación Mutua Madrileña (Mutua Madrileña Foundation) AP165902017Instituto de Salud Carlos III and European Union PI17/00115, PI20/00164Ministerio de Ciencia, Innovación y Universidades (MCIU) PID2021-124062NB-100Ministerio de Ciencia, Innovación y Universidades (MCIU) RTI2018-094004-B-100Red Española de Investigación en Patologías Infeccionas, European Development Regional Fund "A way to achieve Europe" (ERDF), Vertex Pharmaceuticals RD16/0016/0011
6 · The paper itself

Abstract

We report a metaproteomic analysis of the gut microbiota of eight infants with cystic fibrosis, during the first year of life. This is the first study in this disease that uses metaproteomics to analyze stool samples from patients at such a young age.

Indexed as

cystic fibrosisgut microbiotametaproteomics

Identifiers

PMID38967490
PMCPMC11320925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.